⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316745 | 1.00 | — | — | |
| SCHEMBL3314794 | 1.00 | — | — | |
| SCHEMBL2223367 | 0.71 | — | — | |
| SCHEMBL1972830 | 0.71 | — | — | |
| SCHEMBL2223594 | 0.71 | — | — | |
| SCHEMBL354092 | 0.62 | — | — | |
| SCHEMBL1430561 | 0.62 | — | — | |
| SCHEMBL2043950 | 0.62 | — | — | |
| SCHEMBL7993529 | 0.62 | — | — | |
| SCHEMBL2043460 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | claimed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | claimed |
| WO-2024042494-A1 | SUBSTITUTED PYRROLOTRIAZINES | MOLECURE SA (PL) | 2024-02-29 | — | — | WO | claimed |
| CN-112236431-B | Purinone Compounds and Their Use in the Treatment of Cancer | 阿斯利康(瑞典)有限公司 | 2024-02-13 | — | — | CN | claimed |
| US-11884671-B2 | Purinone compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2024-01-30 | — | — | US | claimed |
| CN-116888112-A | Lactams as CBL-B inhibitors | 基因泰克公司 | 2023-10-13 | — | — | CN | claimed |
| EP-3442977-B1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORP (US) | 2023-06-28 | — | — | EP | claimed |
| CN-109311889-B | Activin receptor-like kinase inhibitors | 缆图药品公司 | 2021-11-16 | — | — | CN | claimed |
| US-20210171525-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-10 | — | — | US | claimed |
| EP-3807278-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2021-04-21 | — | — | EP | claimed |
| CN-112236431-A | Purinone compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2021-01-15 | — | — | CN | claimed |
| WO-2019238929-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2019-12-19 | — | — | WO | claimed |
| EP-3442977-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | Blueprint Medicines Corporation (US) | 2019-02-20 | — | — | EP | claimed |
| WO-2017181117-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION (US) | 2017-10-19 | — | — | WO | claimed |
| US-20240158398-A1 | INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE | BLUEPRINT MEDICINES CORPORATION | 2024-05-16 | — | — | US | disclosed |
| US-20240150355-A1 | PURINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2024-05-09 | — | — | US | disclosed |
| US-20240150362-A1 | Substituted Pyrrolotriazines | MOLECURE S.A. (PL) | 2024-05-09 | — | — | US | disclosed |
| EP-3030560-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd (CH) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015019325-A1 | BENZIMIDAZOLYL-METHYL UREA DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-02-12 | — | — | WO | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |